Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Evoke Pharma, Inc. (EVOK) had Return on Tangible Equity of -35.91% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$3.75M |
|
$-1.57M |
|
$0.17M |
|
$3.58M |
|
$5.31M |
|
$-1.56M |
|
$-0.01M |
|
$-1.57M |
|
$-1.57M |
|
$-1.57M |
|
$-1.57M |
|
$-1.57M |
|
$-1.57M |
|
$-1.56M |
|
$-1.56M |
|
2.55M |
|
2.55M |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$15.93M |
|
-- |
|
$0.13M |
|
$16.06M |
|
$11.62M |
|
-- |
|
$0.07M |
|
$11.69M |
|
$4.37M |
|
$4.37M |
|
$4.37M |
|
1.49M |
|
| Cash Flow Statement Financials | |
$-1.56M |
|
-- |
|
$0.03M |
|
$13.60M |
|
$12.06M |
|
$-1.54M |
|
$0.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.37 |
|
-- |
|
-- |
|
-- |
|
1.14 |
|
95.53% |
|
-41.55% |
|
-41.55% |
|
-- |
|
-41.87% |
|
-41.87% |
|
$-1.56M |
|
-- |
|
-- |
|
-- |
|
0.23 |
|
0.26 |
|
1.29 |
|
69.69 |
|
-35.91% |
|
|
Return on Tangible Equity |
-35.91% |
-9.78% |
|
-35.91% |
|
$2.93 |
|
$-0.61 |
|
$-0.61 |
|